首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   746篇
  免费   16篇
  国内免费   8篇
  770篇
  2024年   2篇
  2023年   11篇
  2022年   15篇
  2021年   3篇
  2020年   16篇
  2019年   11篇
  2018年   19篇
  2017年   23篇
  2016年   29篇
  2015年   6篇
  2014年   88篇
  2013年   138篇
  2012年   4篇
  2011年   53篇
  2010年   44篇
  2009年   47篇
  2008年   35篇
  2007年   51篇
  2006年   35篇
  2005年   16篇
  2004年   13篇
  2003年   13篇
  2002年   12篇
  2001年   17篇
  2000年   12篇
  1999年   8篇
  1998年   10篇
  1997年   14篇
  1996年   6篇
  1995年   6篇
  1994年   7篇
  1992年   1篇
  1991年   3篇
  1988年   1篇
  1986年   1篇
排序方式: 共有770条查询结果,搜索用时 0 毫秒
51.
乳腺癌仍然是严重威胁女性健康的重大疾病。每年新发乳腺癌患者中约有6%为Ⅳ期乳腺癌,而这类患者5年生存率小于20%,局部处理(外科、放疗)可以根除局部病灶及微小转移灶,以延缓或者缓解症状,但是否可以带来生存获益尚无定论。本文对Ⅳ期乳腺癌原发灶的局部处理等方面的若干问题作一综述。  相似文献   
52.
无论是国内还是世界其他国家,乳腺癌近年来已成为女性常患恶性肿瘤之首。早期乳腺癌通过手术、化疗、放疗及内分泌治疗等综合治疗后可以达到长期生存。然而对于晚期乳腺癌,特别是伴有远处转移的乳腺癌,疗效却不尽如人意。对于转移性乳腺癌,目前治疗优先选择毒性尽可能小的全身系统性治疗方案;而对于需要缓解症状或避免即将发生并发症(如皮肤溃疡、出血、真菌感染以及疼痛等)的情况可于全身治疗后行相应手术。然而对于转移性乳腺癌是否手术切除原发灶以及是否可从手术中获益,仍然充满争议。  相似文献   
53.
分析多西他赛联合卡铂方案在三阴性乳腺癌新辅助化疗中的疗效及不良反应。分析2010年03月~2013年09月我院收治的84例TNBC患者临床资料,分析对比多西他赛联合卡铂(TP)方案与吡柔比星、氟尿嘧啶、环磷酰胺(CAF)方案新辅助化疗疗效及不良反应。TP组患者的有效率(RR)优于CAF组,P<0.05。两组患者的药物不良反应无明显差异,P>0.05。多西他赛联合卡铂方案用于三阴性乳腺癌新辅助化疗,疗效确切,耐受性良好。  相似文献   
54.
射频消融术(RFA )、肝动脉化疗栓塞术(TACE)及 DC-CIK 治疗等非手术方法已成为治疗小肝癌的重要手段。RFA 及 TACE 直接杀伤肿瘤细胞,DC-CIK 治疗明显改善机体免疫功能。 TACE 联合 RFA 术后序贯 DC-CIK 治疗可取长补短,提高治疗的有效性、安全性及患者的远期疗效。本文主要对 DC-CIK 治疗、TACE 、RFA 治疗现状及联合治疗前景做一综述。  相似文献   
55.
如何利用伊斯兰教的信仰关怀、情感关怀和死亡关怀“三关怀”,提高癌症患者临终关怀质量和癌性疼痛心理治疗效果,作者根据在宁夏回族地区癌症患者中开展临终关怀的五年实践体会,从临终关怀的宗旨和目的出发,探讨了伊斯兰教的临终关怀之信仰关怀、情感关怀和死亡关怀三种形式和内容,解释了癌性疼痛的原因、疼痛的主观和客观影响因素及心理治疗的常用方法和原则,总结了在宁夏回族地区开展临终关怀应用伊斯兰教的信仰关怀、情感关怀和死亡关怀”三关怀”与癌性疼痛心理治疗之间的关系。  相似文献   
56.
恶性肿瘤的治疗已经进入驱动基因指导下的个体治疗时代,肺癌患者应该进行多基因检测,特别是表皮生长因子受体(EGFR)基因突变。EGFR基因突变的非小细胞肺癌(NSCLC)患者,如果一线接受了化疗,二线应该选择表皮生长因子受体一酪氨酸酶抑制剂(EGFR—TKIs)。EGFR基因突变的NSCLC患者一线EGFR—TKIs治疗失败后,二线治疗应该是个体化合理选择,包括局部放疗、化疗和继续EGFR—TKIs。目前一代和二代EGFR—TKIs药物之间未见到显著疗效差别。第三代EGFR—TKIs是目前的EGFR—TKIs耐药后的最有希望的选择,特别是针对T790M突变耐药。  相似文献   
57.
研究胰岛素样生长因子结合蛋白2(IGFBP-2)及胰岛素样生长因子结合蛋白6(IGFBP-6)在结直肠癌中的表达及临床意义。采用免疫组织化学法及RT-PCR方法检测结直肠癌、结直肠腺瘤及癌旁正常黏膜组织中IGFBP-2及IGFBP-6的蛋白及mRNA的表达情况,结合临床病理资料进行统计学分析。IGFBP-2及IGFBP-6蛋白的阳性表达及mRNA的表达量在三组组织中均存在异常表达情况,且差异有明显的统计学意义(P〈0.05),在结直肠癌组IGFBP-2、IGFBP-6的阳性表达在肿瘤浸润深度、有无淋巴结转移及Duke's分期存在差异,有明显的统计学差异(P〈0.05)。临床可以把二者作为结直肠癌诊断及预后的早期预测指标。  相似文献   
58.
Survivors of lung or head and neck cancers often change tobacco and alcohol consumption after diagnosis, but few studies have examined other positive health changes (PHCs) or their determinants in these groups. The present study aims to: (a) document PHCs in survivors of lung (n?=?107) or head and neck cancers (n?=?99) and (b) examine behavioural self-blame and stigma as determinants of PHCs. We hypothesised that: (a) survivors would make a variety of PHCs; (b) behavioural self-blame for the disease would positively predict making PHCs; and (c) stigma would negatively predict making PHCs.

Methods: Respondents self-administered measures of PHC, behavioural self-blame, and stigma. Hierarchical multiple regression analysis tested the hypotheses.

Results: More than 65% of respondents reported making PHCs, the most common being changes in diet (25%), exercise (23%) and tobacco consumption (16.5%). Behavioural self-blame significantly predicted PHCs but stigma did not. However, both behavioural self-blame and stigma significantly predicted changes in tobacco consumption.

Conclusions: Many survivors of lung or head and neck cancers engage in PHCs, but those who do not attribute the disease to their behaviour are less likely to do so. Attention to this problem and additional counselling may help people to adopt PHCs.  相似文献   
59.
Objectives: Weight cycling is linked with advanced breast cancer diagnosis, increased risk of cancer reoccurrence and cancer-related mortality. While women treated for breast cancer report challenges with navigating their post-treatment body shape and weight, the effects of weight cycling on body image and mental health have not been elucidated. This study examined associations between weight changes and weight cycling on psychological health (i.e. weight-related guilt, shame and depressive symptoms) among women in the first-year post-treatment.

Design and Outcome Measures: Self-reported assessments of pre-cancer weight cycling, post-treatment weight-related guilt, shame and depressive symptoms, and objective assessments of weight were assessed in a longitudinal sample of 173 women treated for breast cancer (Mage = 55.01 ± 10.96 years).

Results: Based on findings from multilevel models, women experienced the most weight-related shame when their weight was heavier than their personal average. Additionally, heavier weight was associated with worse psychological health, particularly for women with a history of stable (vs. cycling) weight pre-cancer.

Conclusions: Weight cycling pre-cancer and post-treatment weight change have important implications for psychological well-being. Due to the potential psychological consequences associated with a history of weight cycling, targeted strategies are needed to improve overall health outcomes for women’s survivorship after breast cancer.  相似文献   

60.
Nearly half of all cancer deaths are attributable to preventable causes, primarily unhealthy behaviours such as tobacco use, alcohol use and overeating. In this review, we argue that people engage in these behaviours, at least in part, as a means of regulating their affective states. To better understand why people engage in these behaviours and how researchers might design interventions to promote the selection of healthier methods for regulating affect, we propose a conceptual model of affect regulation. We synthesise research from both the stress and coping tradition as well as the emotion and emotion regulation tradition, two literatures that are not typically integrated. In so doing, we indicate where researchers have made headway in understanding these behaviours as affect regulation and note how our model could be used to structure future work in a way that would be particularly advantageous to cancer control efforts.  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号